Search / Trial NCT00001082

The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of March 02, 2024

Completed

Keywords

Cytomegalovirus Infections Antiviral Agents Cd4 Lymphocyte Count Prodrugs Survival Adenine

Description

The optimal treatment for HIV infection and the prevention of CMV disease has not been identified. Currently available antiretroviral therapies are hampered by both significant toxicities and the development of resistance. In addition, agents for preventing CMV disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased compliance secondary to toxicities. Moreover, discordant results have been reported regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need for newer agents with anti-HIV and anti-herpesvirus activity that have...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Chronically administered concomitant therapies for HIV and opportunistic diseases, including chemotherapy for cutaneous Kaposi's sarcoma, must be on these therapies for at least 30 days prior to study entry.
  • Short courses of oral antibiotics or other therapies given for a limited period of 3 weeks.
  • Episodic use of IV acyclovir or oral acyclovir > 1g/day for treatment of acute illness is permitted at the clinician's discretion.
  • Patients must have:
  • A working diagnosis of HIV infection based on the patient's medical history, behavioral history, clinical signs and symptoms, or results of other laboratory tests.
  • CD4+ cell count <= 100 cells/mm3 within 60 days prior to randomization (OR, AS PER AMENDMENT 8/7/97, a CD4+ cell count that is both > 100 and <= 200 cells/mm3 within 60 days prior to randomization and a documented nadir CD4+ cell count <= 50 cells/ mm3 at any time prior to randomization).
  • Reasonably good health.
  • Life expectancy of at least 6 months.
  • Access to a refrigerator for the storage of adefovir dipivoxil.
  • Signed informed consent from parent or legal guardian for patients less than 18 years of age.
  • AS PER AMENDMENT 8/7/97:
  • CMV serology (IgG) positive (CMV bDNA cohort and CMV-virology cohort).
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms and conditions are excluded:
  • Evidence of active CMV disease at screening.
  • Conditions that would require use of medications listed in Exclusion Concurrent Medications.
  • Concurrent Medication:
  • Excluded:
  • Any investigational anti-CMV agent.
  • Adenine arabinoside (vidarabine).
  • Amantadine hydrochloride (Symmetrel).
  • Cidofovir (Vistide).
  • CMV hyperimmune globulin.
  • Cytosine arabinoside (cytarabine).
  • Famciclovir.
  • Foscarnet (phosphonoformic acid).
  • Ganciclovir (Cytovene).
  • GW 1263W94 (Benzamidazole).
  • Idoxuridine.
  • Intravenous acyclovir.
  • ISIS 2922 (Anti-sense).
  • Lobucavir.
  • MSL109.
  • Oral acyclovir > 1 g/day.
  • Valacyclovir.
  • Patients with the following prior conditions are excluded:
  • History of CMV end-organ disease.
  • Prior Medication:
  • Excluded within 2 weeks of randomization:
  • Any investigational anti-CMV agent.
  • Adenine arabinoside (vidarabine).
  • Amantadine hydrochloride (Symmetrel).
  • Cidofovir (Vistide).
  • CMV hyperimmune globulin.
  • Cytosine arabinoside (cytarabine).
  • Famciclovir.
  • Ganciclovir (Cytovene).
  • GW 1263W94 (Benzamidazole).
  • Idoxuridine.
  • Intravenous acyclovir.
  • ISIS 2922 (Anti-sense).
  • Lobucavir.
  • MSL109.
  • Oral acyclovir > 1 g/day.
  • Valacyclovir.
  • Excluded within 60 days prior to study entry:
  • Foscarnet.

Attachments

readout_NCT00001082_2024-03-02.pdf

4.5 MB

NCT00001082_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

San Francisco, California, United States

Denver, Colorado, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

New Orleans, Louisiana, United States

Detroit, Michigan, United States

Camden, New Jersey, United States

Newark, New Jersey, United States

Philadelphia, Pennsylvania, United States

Washington, District Of Columbia, United States

Portland, Oregon, United States

Albuquerque, New Mexico, United States

Detroit, Michigan, United States

New York, New York, United States

Richmond, Virginia, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Throughout study

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0